Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Malaria

Free Subscription Articles published in Vaccine Retrieve available abstracts of 50 articles: HTML format Text format

Single Articles

January 2012
1. BREMAN JG , Brandling-Bennett AD
   The challenge of malaria eradication in the twenty-first century: Research linked to operations is the key.
   Vaccine. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. TANABE K , Arisue N, Palacpac NM, Yagi M, et al
   Geographic differentiation of polymorphism in the Plasmodium falciparum malaria vaccine candidate gene SERA5.
   Vaccine. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   November 2011
3. PINTO VV , Salanti A, Joergensen LM, Dahlback M, et al
   The effect of adjuvants on the immune response induced by a DBL4varepsilon-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria.
   Vaccine. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. MIYATA T , Harakuni T, Taira T, Matsuzaki G, et al
   Merozoite surface protein-1 of Plasmodium yoelii fused via an oligosaccharide moiety of cholera toxin B subunit glycoprotein expressed in yeast induced protective immunity against lethal malaria infection in mice.
   Vaccine. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   October 2011
5. TETTEH KK , Conway DJ
   A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1.
   Vaccine. 2011;29:7811-7.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. SCHWENK R , Lumsden JM, Rein LE, Juompan L, et al
   Immunization with the RTS,S/AS malaria vaccine induces IFN-gamma+CD4 T cells that recognize only discrete regions of the circumsporozoite protein and these specificities are maintained following booster immunizations and challenge.
   Vaccine. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   September 2011
7. CHERIF MS , Shuaibu MN, Kurosaki T, Helegbe GK, et al
   Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration.
   Vaccine. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   July 2011
8. OLUGBILE S , Villard V, Bertholet S, Jafarshad A, et al
   Malaria vaccine candidate: Design of a multivalent subunit alpha-helical coiled coil poly-epitope.
   Vaccine. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. FRIESEN J , Matuschewski K
   Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite.
   Vaccine. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   June 2011
10. BERGMANN-LEITNER ES , Legler PM, Savranskaya T, Ockenhouse CF, et al
    Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. PALACPAC NM , Arisue N, Tougan T, Ishii KJ, et al
    Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
12. DOI M , Tanabe K, Tachibana SI, Hamai M, et al
    Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax.
    Vaccine. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
13. PORTER DW , Thompson FM, Berthoud TK, Hutchings CL, et al
    A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
14. AIDE P , Dobano C, Sacarlal J, Aponte JJ, et al
    Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. ZHU D , McClellan H, Dai W, Gebregeorgis E, et al
    Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide((R)) ISA 720 and stabilized with glycine.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
16. SHUAIBU MN , Cherif MS, Kurosaki T, Helegbe GK, et al
    Effect of nanoparticle coating on the immunogenicity of plasmid DNA vaccine encoding P. yoelii MSP-1 C-terminal.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. LOUSADA-DIETRICH S , Jogdand PS, Jepsen S, Pinto VV, et al
    A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - A GLURP-MSP3 fusion protein malaria vaccine candidate.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. PALMA C , Overstreet MG, Guedon JM, Hoiczyk E, et al
    Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice.
    Vaccine. 2011;29:1683-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. MIYATA T , Harakuni T, Sugawa H, Sattabongkot J, et al
    Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. CAVANAGH DR , Dubois PM, Kisser A, Leroy O, et al
    Towards validated assays for key immunological outcomes in malaria vaccine development.
    Vaccine. 2011.
    PubMed     Text format     Related articles   
    
    
    
    January 2011
21. MIURA K , Zhou H, Diouf A, Tullo G, et al
    Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. MAGISTRADO PA , Minja D, Doritchamou J, Ndam NT, et al
    High efficacy of anti DBL4varepsilon-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women.
    Vaccine. 2011;29:437-43.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. LIMA-JUNIOR JC , Jiang J, Rodrigues-da-Silva RN, Banic DM, et al
    B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax Merozoite Surface Protein-3alpha (PvMSP-3alpha) in malaria exposed individuals from Brazilian Amazon.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
24. ELLIOTT AM , Mawa PA, Webb EL, Nampijja M, et al
    Effects of maternal and infant co-infections, and of maternal immunisation, on the infant response to BCG and tetanus immunisation.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. CAPONE S , Reyes-Sandoval A, Naddeo M, Siani L, et al
    Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. TEWARI K , Flynn BJ, Boscardin SB, Kastenmueller K, et al
    Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates.
    Vaccine. 2010;28:7256-66.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. DOUGLAS AD , de Cassan SC, Dicks MD, Gilbert SC, et al
    Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.
    Vaccine. 2010;28:7167-78.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. JIANG B , Qin L, Du Y, Peng N, et al
    Transgenic Plasmodium that expresses HIV-1 Gag elicits immunity and protects mice against vaccinia virus-gag and malarial parasites.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
29. MLAMBO G , Kumar N, Shigeto Y
    Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. SHUAIBU MN , Kikuchi M, Cherif MS, Helegbe GK, et al
    Selection and identification of malaria vaccine target molecule using bioinformatics and DNA vaccination.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. ALARO JR , Lynch MM, Burns JM Jr
    Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. MORDMULLER B , Szywon K, Greutelaers B, Esen M, et al
    Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. GENTON B , D'Acremont V, Lurati-Ruiz F, Verhage D, et al
    Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
34. SIRUGO G , Williams SM
    HbS and HbC associate with malaria transmission: Human genetics links to vaccinology?
    Vaccine. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
35. BLAGBOROUGH AM , Yoshida S, Sattabongkot J, Tsuboi T, et al
    Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. BERMUDEZ A , Alba MP, Vanegas M, Patarroyo ME, et al
    3D structure determination of STARP peptides implicated in P. falciparum invasion of hepatic cells.
    Vaccine. 2010;28:4989-96.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. CUMMINGS JF , Spring MD, Schwenk RJ, Ockenhouse CF, et al
    Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
    Vaccine. 2010;28:5135-44.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2010
38. CASARES S , Brumeanu TD, Richie TL
    The RTS,S malaria vaccine.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. PINDER M , Moorthy VS, Akanmori BD, Genton B, et al
    MALVAC 2009: Progress and Challenges in Development of Whole Organism Malaria Vaccines for Endemic Countries, 3-4 June 2009, Dakar, Senegal.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. STOYANOV CT , Boscardin SB, Deroubaix S, Barba-Spaeth G, et al
    Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2010
41. WEISS R , Gabler M, Jacobs T, Gilberger TW, et al
    Differential effects of C3d on the immunogenicity of gene gun vaccines encoding Plasmodium falciparum and Plasmodium berghei MSP1(42).
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2010
42. JONGWUTIWES S , Putaporntip C, Hughes AL
    Bottleneck effects on vaccine-candidate antigen diversity of malaria parasites in Thailand.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. LIMA JC JR , Banic DM, Tran TM, Meyer VS, et al
    Promiscuous T-cell epitopes of Plasmodium merozoite surface protein 9 (PvMSP9) induces IFN-gamma and IL-4 responses in individuals naturally exposed to malaria in the Brazilian Amazon.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. BRUDER JT , Stefaniak ME, Patterson NB, Chen P, et al
    Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2010
45. SINGH B , Cabrera-Mora M, Jiang J, Galinski M, et al
    Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. PINZON CG , Curtidor H, Garcia J, Vanegas M, et al
    Sequences of the Plasmodium falciparum cytoadherence-linked asexual protein 9 implicated in malaria parasite invasion to erythrocytes.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2009
47. BALOGUN HA , Vasconcelos NM, Lindberg R, Haeggstrom M, et al
    Immunogenicity and antigenic properties of Pf332-C231, a fragment of a non-repeat region of the Plasmodium falciparum antigen Pf332.
    Vaccine. 2009;28:90-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. TRAORE B , Kone Y, Doumbo S, Doumtabe D, et al
    The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali.
    Vaccine. 2009;27:7299-303.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2009
49. BRAGA CJ , Massis LM, Sbrogio-Almeida ME, Alencar BC, et al
    CD8(+) T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2009
50. GIRALDO MA , Arevalo-Pinzon G, Rojas-Caraballo J, Mongui A, et al
    Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: